Current Treatment Options for Diabetic Retinal Disease
RF Bloomquist, DT Bloomquist… - Diabetes Technology & …, 2024 - liebertpub.com
The global incidence of diabetes is rising steadily and with it the number of people living
with diabetic retinal disease (DRD) is increasing. Like diabetes, DRD can be treated but not …
with diabetic retinal disease (DRD) is increasing. Like diabetes, DRD can be treated but not …
[HTML][HTML] Impact of duration of treatments with metformin and sulfonylureas, individually or in combination, on diabetic retinopathy among newly diagnosed type 2 …
Background This study aimed to evaluate the effect of metformin and sulfonylurea (SUs)
medication time on Diabetic retinopathy (DR) among newly diagnosed patients with type 2 …
medication time on Diabetic retinopathy (DR) among newly diagnosed patients with type 2 …
SGLT2 inhibitors and diabetic retinopathy: Insights from the management of nephropathy
MS Varughese, L Varadhan - Eye, 2024 - nature.com
Diabetic retinopathy (DR) continues to be a leading cause for diabetic macular oedema
(DMO) and complete vision loss. Recent demographic data suggests that in 2020 …
(DMO) and complete vision loss. Recent demographic data suggests that in 2020 …
Novel Agents in the Management of Diabetes and Risk of Worsening Diabetic Retinopathy
R Rajagopal, JB McGill - Retina, 2022 - journals.lww.com
Purpose: Novel therapies for diabetes have potent effects on glycemic control, obesity and
cardiovascular risk reduction but some, including the popular drug semaglutide, have also …
cardiovascular risk reduction but some, including the popular drug semaglutide, have also …
[PDF][PDF] Does Saving the Kidneys Mean Risking the Eyes?
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) such as semaglutide have been a
breakthrough therapy for many patients with type 2 diabetes and/or obesity. Beyond weight …
breakthrough therapy for many patients with type 2 diabetes and/or obesity. Beyond weight …